Serveur d'exploration sur le lymphœdème

Attention, ce site est en cours de développement !
Attention, site généré par des moyens informatiques à partir de corpus bruts.
Les informations ne sont donc pas validées.

B-type natriuretic peptide in lymphedema.

Identifieur interne : 005062 ( Main/Exploration ); précédent : 005061; suivant : 005063

B-type natriuretic peptide in lymphedema.

Auteurs : J. Todd [Royaume-Uni] ; T. Austwick ; D. Berridge ; L B Tan ; J H Barth

Source :

RBID : pubmed:21667820

Descripteurs français

English descriptors

Abstract

Lymphedema often responds to compression therapy which can also cause undesirable cardiac overload if heart failure coexists. We hypothesized that the biomarker B-type natriuretic peptide (BNP) can be used to screen lymphedema patients for undetected cardiac dysfunction. We studied unselected consecutive patients with lymphedema to determine their BNP status and compared these data with those obtained from healthy subjects without known cardiovascular diseases. Out of a total of 305 subjects with lymphedema screened, 102 (33%) consented to take part in this study. The majority (87%) were female with a mean age of 60.5 +/- 13.2 (SD) years, and 47% had just lower limb swelling. The groups were equally divided between cancer and non-cancer related causes. There were 45 females and 4 males under 60 years old, and 44 female and 9 male patients over 60 years old. Median (IQR) BNP (ng/L) were as follows: <60 years females = 17.9 (15.2) (median [RR: 3 - 64] and males = 12.4 (14.7) [RR: 0.2 - 44], >60 years females = 35.8 (57.9) [RR: 2 -247)] and males = 47.2 (44.1) [RR: 2 - 238]. For this population, the BNP concentration 100 ng/L was adopted as the value to exclude heart failure. Using this definition, 7 lymphedema subjects had BNP concentrations of 120 (19.8) ng/L, and all were found to have cardiac abnormalities on echocardiography. This study demonstrated that 93% of unselected subjects with lymphedema had BNP concentrations that exclude a diagnosis of heart failure. Those subjects with elevated BNP were found on subsequent echocardiography to have cardiac abnormalities. The use of a BNP assay is of potential value in screening patients who are more likely to have cardiac failure. Indicative factors include bilateral leg swelling, over the age of 50 years, breathlessness, where there is no known cause for the swelling. A BNP assay using a BNP concentration threshold of 100 ng/L (29 pmol/L) will identify those patients who require more detailed investigations.

PubMed: 21667820


Affiliations:


Links toward previous steps (curation, corpus...)


Le document en format XML

<record>
<TEI>
<teiHeader>
<fileDesc>
<titleStmt>
<title xml:lang="en">B-type natriuretic peptide in lymphedema.</title>
<author>
<name sortKey="Todd, J" sort="Todd, J" uniqKey="Todd J" first="J" last="Todd">J. Todd</name>
<affiliation wicri:level="1">
<nlm:affiliation>Department of Lymphoedema, Leeds Teaching Hospitals NHS Trust, Leeds. Jacquelyne.Todd@leedsth.nhs.uk</nlm:affiliation>
<country wicri:rule="url">Royaume-Uni</country>
</affiliation>
</author>
<author>
<name sortKey="Austwick, T" sort="Austwick, T" uniqKey="Austwick T" first="T" last="Austwick">T. Austwick</name>
</author>
<author>
<name sortKey="Berridge, D" sort="Berridge, D" uniqKey="Berridge D" first="D" last="Berridge">D. Berridge</name>
</author>
<author>
<name sortKey="Tan, L B" sort="Tan, L B" uniqKey="Tan L" first="L B" last="Tan">L B Tan</name>
</author>
<author>
<name sortKey="Barth, J H" sort="Barth, J H" uniqKey="Barth J" first="J H" last="Barth">J H Barth</name>
</author>
</titleStmt>
<publicationStmt>
<idno type="wicri:source">PubMed</idno>
<date when="2011">2011</date>
<idno type="RBID">pubmed:21667820</idno>
<idno type="pmid">21667820</idno>
<idno type="wicri:Area/PubMed/Corpus">002587</idno>
<idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Corpus" wicri:corpus="PubMed">002587</idno>
<idno type="wicri:Area/PubMed/Curation">002587</idno>
<idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Curation">002587</idno>
<idno type="wicri:Area/PubMed/Checkpoint">002587</idno>
<idno type="wicri:explorRef" wicri:stream="Checkpoint" wicri:step="PubMed">002587</idno>
<idno type="wicri:Area/Ncbi/Merge">004421</idno>
<idno type="wicri:Area/Ncbi/Curation">004421</idno>
<idno type="wicri:Area/Ncbi/Checkpoint">004421</idno>
<idno type="wicri:doubleKey">0024-7766:2011:Todd J:b:type:natriuretic</idno>
<idno type="wicri:Area/Main/Merge">005100</idno>
<idno type="wicri:Area/Main/Curation">005062</idno>
<idno type="wicri:Area/Main/Exploration">005062</idno>
</publicationStmt>
<sourceDesc>
<biblStruct>
<analytic>
<title xml:lang="en">B-type natriuretic peptide in lymphedema.</title>
<author>
<name sortKey="Todd, J" sort="Todd, J" uniqKey="Todd J" first="J" last="Todd">J. Todd</name>
<affiliation wicri:level="1">
<nlm:affiliation>Department of Lymphoedema, Leeds Teaching Hospitals NHS Trust, Leeds. Jacquelyne.Todd@leedsth.nhs.uk</nlm:affiliation>
<country wicri:rule="url">Royaume-Uni</country>
</affiliation>
</author>
<author>
<name sortKey="Austwick, T" sort="Austwick, T" uniqKey="Austwick T" first="T" last="Austwick">T. Austwick</name>
</author>
<author>
<name sortKey="Berridge, D" sort="Berridge, D" uniqKey="Berridge D" first="D" last="Berridge">D. Berridge</name>
</author>
<author>
<name sortKey="Tan, L B" sort="Tan, L B" uniqKey="Tan L" first="L B" last="Tan">L B Tan</name>
</author>
<author>
<name sortKey="Barth, J H" sort="Barth, J H" uniqKey="Barth J" first="J H" last="Barth">J H Barth</name>
</author>
</analytic>
<series>
<title level="j">Lymphology</title>
<idno type="ISSN">0024-7766</idno>
<imprint>
<date when="2011" type="published">2011</date>
</imprint>
</series>
</biblStruct>
</sourceDesc>
</fileDesc>
<profileDesc>
<textClass>
<keywords scheme="KwdEn" xml:lang="en">
<term>Adult</term>
<term>Biomarkers (blood)</term>
<term>Female</term>
<term>Heart Failure (blood)</term>
<term>Heart Failure (diagnosis)</term>
<term>Heart Failure (etiology)</term>
<term>Humans</term>
<term>Lymphedema (blood)</term>
<term>Lymphedema (complications)</term>
<term>Male</term>
<term>Middle Aged</term>
<term>Natriuretic Peptide, Brain (blood)</term>
</keywords>
<keywords scheme="KwdFr" xml:lang="fr">
<term>Adulte</term>
<term>Adulte d'âge moyen</term>
<term>Défaillance cardiaque (diagnostic)</term>
<term>Défaillance cardiaque (sang)</term>
<term>Défaillance cardiaque (étiologie)</term>
<term>Femelle</term>
<term>Humains</term>
<term>Lymphoedème ()</term>
<term>Lymphoedème (sang)</term>
<term>Marqueurs biologiques (sang)</term>
<term>Mâle</term>
<term>Peptide natriurétique cérébral (sang)</term>
</keywords>
<keywords scheme="MESH" type="chemical" qualifier="blood" xml:lang="en">
<term>Biomarkers</term>
<term>Natriuretic Peptide, Brain</term>
</keywords>
<keywords scheme="MESH" qualifier="blood" xml:lang="en">
<term>Heart Failure</term>
<term>Lymphedema</term>
</keywords>
<keywords scheme="MESH" qualifier="complications" xml:lang="en">
<term>Lymphedema</term>
</keywords>
<keywords scheme="MESH" qualifier="diagnosis" xml:lang="en">
<term>Heart Failure</term>
</keywords>
<keywords scheme="MESH" qualifier="diagnostic" xml:lang="fr">
<term>Défaillance cardiaque</term>
</keywords>
<keywords scheme="MESH" qualifier="etiology" xml:lang="en">
<term>Heart Failure</term>
</keywords>
<keywords scheme="MESH" qualifier="sang" xml:lang="fr">
<term>Défaillance cardiaque</term>
<term>Lymphoedème</term>
<term>Marqueurs biologiques</term>
<term>Peptide natriurétique cérébral</term>
</keywords>
<keywords scheme="MESH" qualifier="étiologie" xml:lang="fr">
<term>Défaillance cardiaque</term>
</keywords>
<keywords scheme="MESH" xml:lang="en">
<term>Adult</term>
<term>Female</term>
<term>Humans</term>
<term>Male</term>
<term>Middle Aged</term>
</keywords>
<keywords scheme="MESH" xml:lang="fr">
<term>Adulte</term>
<term>Adulte d'âge moyen</term>
<term>Femelle</term>
<term>Humains</term>
<term>Lymphoedème</term>
<term>Mâle</term>
</keywords>
</textClass>
</profileDesc>
</teiHeader>
<front>
<div type="abstract" xml:lang="en">Lymphedema often responds to compression therapy which can also cause undesirable cardiac overload if heart failure coexists. We hypothesized that the biomarker B-type natriuretic peptide (BNP) can be used to screen lymphedema patients for undetected cardiac dysfunction. We studied unselected consecutive patients with lymphedema to determine their BNP status and compared these data with those obtained from healthy subjects without known cardiovascular diseases. Out of a total of 305 subjects with lymphedema screened, 102 (33%) consented to take part in this study. The majority (87%) were female with a mean age of 60.5 +/- 13.2 (SD) years, and 47% had just lower limb swelling. The groups were equally divided between cancer and non-cancer related causes. There were 45 females and 4 males under 60 years old, and 44 female and 9 male patients over 60 years old. Median (IQR) BNP (ng/L) were as follows: <60 years females = 17.9 (15.2) (median [RR: 3 - 64] and males = 12.4 (14.7) [RR: 0.2 - 44], >60 years females = 35.8 (57.9) [RR: 2 -247)] and males = 47.2 (44.1) [RR: 2 - 238]. For this population, the BNP concentration 100 ng/L was adopted as the value to exclude heart failure. Using this definition, 7 lymphedema subjects had BNP concentrations of 120 (19.8) ng/L, and all were found to have cardiac abnormalities on echocardiography. This study demonstrated that 93% of unselected subjects with lymphedema had BNP concentrations that exclude a diagnosis of heart failure. Those subjects with elevated BNP were found on subsequent echocardiography to have cardiac abnormalities. The use of a BNP assay is of potential value in screening patients who are more likely to have cardiac failure. Indicative factors include bilateral leg swelling, over the age of 50 years, breathlessness, where there is no known cause for the swelling. A BNP assay using a BNP concentration threshold of 100 ng/L (29 pmol/L) will identify those patients who require more detailed investigations.</div>
</front>
</TEI>
<affiliations>
<list>
<country>
<li>Royaume-Uni</li>
</country>
</list>
<tree>
<noCountry>
<name sortKey="Austwick, T" sort="Austwick, T" uniqKey="Austwick T" first="T" last="Austwick">T. Austwick</name>
<name sortKey="Barth, J H" sort="Barth, J H" uniqKey="Barth J" first="J H" last="Barth">J H Barth</name>
<name sortKey="Berridge, D" sort="Berridge, D" uniqKey="Berridge D" first="D" last="Berridge">D. Berridge</name>
<name sortKey="Tan, L B" sort="Tan, L B" uniqKey="Tan L" first="L B" last="Tan">L B Tan</name>
</noCountry>
<country name="Royaume-Uni">
<noRegion>
<name sortKey="Todd, J" sort="Todd, J" uniqKey="Todd J" first="J" last="Todd">J. Todd</name>
</noRegion>
</country>
</tree>
</affiliations>
</record>

Pour manipuler ce document sous Unix (Dilib)

EXPLOR_STEP=$WICRI_ROOT/Wicri/Sante/explor/LymphedemaV1/Data/Main/Exploration
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 005062 | SxmlIndent | more

Ou

HfdSelect -h $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd -nk 005062 | SxmlIndent | more

Pour mettre un lien sur cette page dans le réseau Wicri

{{Explor lien
   |wiki=    Wicri/Sante
   |area=    LymphedemaV1
   |flux=    Main
   |étape=   Exploration
   |type=    RBID
   |clé=     pubmed:21667820
   |texte=   B-type natriuretic peptide in lymphedema.
}}

Pour générer des pages wiki

HfdIndexSelect -h $EXPLOR_AREA/Data/Main/Exploration/RBID.i   -Sk "pubmed:21667820" \
       | HfdSelect -Kh $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd   \
       | NlmPubMed2Wicri -a LymphedemaV1 

Wicri

This area was generated with Dilib version V0.6.31.
Data generation: Sat Nov 4 17:40:35 2017. Site generation: Tue Feb 13 16:42:16 2024